In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q3 2010

Executive Summary

Medical device financings during the third quarter of 2010 brought in $997 million, an increase of 82% from the second quarter's $548 million. While Q3 M&A activity was down slightly from last quarter - only 15 mergers were completed, compared with 18 in Q2 - more money was involved: an impressive $6.7 billion. The venture rounds for PacBio and Complete Genomics boosted late-stage VC money to $171 million in the third quarter, two-thirds of the entire amount for the in vitro diagnostics/research industry. Despite only five acquisitions closing during the third quarter, the M&A dollar volume for the IVD/research industry was just north of $2 billion.
Advertisement

Related Content

Asthmatx Acquisition By Boston Scientific Is Source of Many Happy Returns
St. Jude Eyes Possible Acquisition Of Heart Failure Monitor Firm CardioMEMS
Sanofi-Aventis' Interest In Genzyme May Include Diagnostics Arm
Medtronic Looks to Strengthen Spine with Osteotech Purchase
The How And When Of Applying Sequencing To Clinical Diagnostics
Welsh Carson Sits in K2M Driver's Seat
Covidien Runs Familiar But Different Plays to Build Vascular Franchise
TriVascular's Sequel Could Be a Blockbuster
TriVascular's Sequel Could Be a Blockbuster
GTCR Dips into Devices with Devicor

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003430

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel